Fig. 1: OS HR by baseline AFP. | British Journal of Cancer

Fig. 1: OS HR by baseline AFP.

From: Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab

Fig. 1

STEPP analysis showing OS HR by median baseline AFP in the a REACH study patients with AFP < 400 ng/ml (ITT population), b REACH study patients with AFP ≥ 400 ng/ml (ITT population), c REACH-2 study (ITT population) and d pooled population of patients with AFP ≥ 400 ng/ml in the REACH-2 and REACH studies. AFP alpha-fetoprotein, HR hazard ratio.

Back to article page